Liminal BioSciences

Liminal BioSciences is committed to the treatment of metabolic, fibrotic, and inflammatory diseases through a drug discovery platform and data-driven approach. The company focuses on developing distinctive novel small molecule therapeutics and has a robust pipeline with potential first-in-class and best-in-class drug candidates. Key programs include a selective GPR84 antagonist for metabolic diseases, NASH/NAFLD, IBD, and IPF; a selective OXER1 antagonist targeting eosinophilic-driven diseases such as eosinophilic asthma and atopic dermatitis; and a GPR40 agonist program focused on insulin resistance and diabetes. The GPR84 antagonist program nominated LMNL6511 as the candidate for clinical development in January 2023, while the OXER1 antagonist program is based on the research of Dr. William Powell and Dr. Joshua Rokach and is currently at the preclinical stage. The GPR40 agonist program, aimed at developing a liver-safe GPR40 agonist for type 2 diabetes, is at the discovery stage. Liminal BioSciences has its registered office in Belleville, Ontario, with talent hubs in Laval, Quebec, Canada, and Cambridge, UK. The company divested its plasma-derived therapeutics business on October 15, 2021, to focus solely on its small molecule therapeutics pipeline. On September 26, 2023, Structured Alpha LP acquired all issued and outstanding common shares not owned by SALP or its affiliates. The company leverages its expertise in GPCRs, the largest family of receptors in the human genome, to develop differentiated GPCR-targeted therapies. Liminal BioSciences aims to build a broader portfolio of novel small molecule compounds, explore collaboration opportunities, and advance the clinical development of its pipeline candidates.